Valeant Pharmaceuticals International, Inc. (VRX, VRX.TO) announced the company now expects fiscal 2016 total revenue to be in the range of $9.9 - $10.1 billion. Adjusted EPS is expected to be in the range of $6.60 - $7.00. In March, the company projected its fiscal 2016 total revenue in a range of $11 billion to $11.2 billion and adjusted earnings per share of $9.50 to $10.50. Analysts polled by Thomson Reuters expect the company to report profit per share of $8.47 on revenue of $10.86 billion. Analysts' estimates typically exclude special items.
from RTT - Earnings http://ift.tt/1UwdMDb
via IFTTT
No comments:
Post a Comment